Cargando…

Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer

BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are known to be associated with response to primary systemic therapy (PST) in breast cancer. This study was conducted to assess the association of TIL subsets with pathological complete response (pCR) after PST in breast cancer in relation to breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, A N, Lee, H J, Kim, E J, Kim, H J, Jang, M H, Lee, H E, Kim, Y J, Kim, J H, Park, S Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833219/
https://www.ncbi.nlm.nih.gov/pubmed/24129232
http://dx.doi.org/10.1038/bjc.2013.634
_version_ 1782291809662140416
author Seo, A N
Lee, H J
Kim, E J
Kim, H J
Jang, M H
Lee, H E
Kim, Y J
Kim, J H
Park, S Y
author_facet Seo, A N
Lee, H J
Kim, E J
Kim, H J
Jang, M H
Lee, H E
Kim, Y J
Kim, J H
Park, S Y
author_sort Seo, A N
collection PubMed
description BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are known to be associated with response to primary systemic therapy (PST) in breast cancer. This study was conducted to assess the association of TIL subsets with pathological complete response (pCR) after PST in breast cancer in relation to breast cancer subtype, breast cancer stem cell (BCSC) phenotype and epithelial–mesenchymal transition (EMT). METHODS: The pre-chemotherapeutic biopsy specimens of 153 breast cancer patients who underwent surgical resection after anthracycline- or anthracycline/taxane-based PST were analysed. TIL subsets (CD4+, CD8+, and FOXP3+ TILs), BCSC phenotype, and the expression of EMT markers were evaluated by immunohistochemistry and were correlated with pCR after PST. RESULTS: Infiltration of CD4+ and CD8+ T lymphocytes was closely correlated with BCSC phenotype and EMT. High levels of CD4+, CD8+, and FOXP3+ TILs were associated with pCR, and CD8+ TILs were found to be an independent predictive factor for pCR. In addition, CD8+ TILs were associated with pCR irrespective of breast cancer subtype, CD44+/CD24− phenotype, EMT, and chemotherapeutic regimen in subgroup analyses. CONCLUSION: These findings indicate that CD8+ cytotoxic T lymphocytes are a key component of TILs associated with chemo-response and can be used as a reliable predictor of response to anthracycline- or anthracycline/taxane-based PST in breast cancer.
format Online
Article
Text
id pubmed-3833219
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-38332192014-11-12 Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer Seo, A N Lee, H J Kim, E J Kim, H J Jang, M H Lee, H E Kim, Y J Kim, J H Park, S Y Br J Cancer Molecular Diagnostics BACKGROUND: Tumour-infiltrating lymphocytes (TILs) are known to be associated with response to primary systemic therapy (PST) in breast cancer. This study was conducted to assess the association of TIL subsets with pathological complete response (pCR) after PST in breast cancer in relation to breast cancer subtype, breast cancer stem cell (BCSC) phenotype and epithelial–mesenchymal transition (EMT). METHODS: The pre-chemotherapeutic biopsy specimens of 153 breast cancer patients who underwent surgical resection after anthracycline- or anthracycline/taxane-based PST were analysed. TIL subsets (CD4+, CD8+, and FOXP3+ TILs), BCSC phenotype, and the expression of EMT markers were evaluated by immunohistochemistry and were correlated with pCR after PST. RESULTS: Infiltration of CD4+ and CD8+ T lymphocytes was closely correlated with BCSC phenotype and EMT. High levels of CD4+, CD8+, and FOXP3+ TILs were associated with pCR, and CD8+ TILs were found to be an independent predictive factor for pCR. In addition, CD8+ TILs were associated with pCR irrespective of breast cancer subtype, CD44+/CD24− phenotype, EMT, and chemotherapeutic regimen in subgroup analyses. CONCLUSION: These findings indicate that CD8+ cytotoxic T lymphocytes are a key component of TILs associated with chemo-response and can be used as a reliable predictor of response to anthracycline- or anthracycline/taxane-based PST in breast cancer. Nature Publishing Group 2013-11-12 2013-10-15 /pmc/articles/PMC3833219/ /pubmed/24129232 http://dx.doi.org/10.1038/bjc.2013.634 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Molecular Diagnostics
Seo, A N
Lee, H J
Kim, E J
Kim, H J
Jang, M H
Lee, H E
Kim, Y J
Kim, J H
Park, S Y
Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
title Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
title_full Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
title_fullStr Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
title_full_unstemmed Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
title_short Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
title_sort tumour-infiltrating cd8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833219/
https://www.ncbi.nlm.nih.gov/pubmed/24129232
http://dx.doi.org/10.1038/bjc.2013.634
work_keys_str_mv AT seoan tumourinfiltratingcd8lymphocytesasanindependentpredictivefactorforpathologicalcompleteresponsetoprimarysystemictherapyinbreastcancer
AT leehj tumourinfiltratingcd8lymphocytesasanindependentpredictivefactorforpathologicalcompleteresponsetoprimarysystemictherapyinbreastcancer
AT kimej tumourinfiltratingcd8lymphocytesasanindependentpredictivefactorforpathologicalcompleteresponsetoprimarysystemictherapyinbreastcancer
AT kimhj tumourinfiltratingcd8lymphocytesasanindependentpredictivefactorforpathologicalcompleteresponsetoprimarysystemictherapyinbreastcancer
AT jangmh tumourinfiltratingcd8lymphocytesasanindependentpredictivefactorforpathologicalcompleteresponsetoprimarysystemictherapyinbreastcancer
AT leehe tumourinfiltratingcd8lymphocytesasanindependentpredictivefactorforpathologicalcompleteresponsetoprimarysystemictherapyinbreastcancer
AT kimyj tumourinfiltratingcd8lymphocytesasanindependentpredictivefactorforpathologicalcompleteresponsetoprimarysystemictherapyinbreastcancer
AT kimjh tumourinfiltratingcd8lymphocytesasanindependentpredictivefactorforpathologicalcompleteresponsetoprimarysystemictherapyinbreastcancer
AT parksy tumourinfiltratingcd8lymphocytesasanindependentpredictivefactorforpathologicalcompleteresponsetoprimarysystemictherapyinbreastcancer